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Malaria is one of the most serious infectious diseases in humans and responsible for approximately 500 million clinical cases and
500 thousand deaths annually. Acquired adaptive immune responses control parasite replication and infection-induced pathologies.
Most infections are clinically silent which reflects on the ability of adaptive immune mechanisms to prevent the disease. However,
a minority of these can become severe and life-threatening, manifesting a range of overlapping syndromes of complex origins
which could be induced by uncontrolled immune responses. Major players of the innate and adaptive responses are interferons.
Here, we review their roles and the signaling pathways involved in their production and protection against infection and induced
immunopathologies.
1. Introduction
Malaria, a mosquito-borne infectious disease transmitted by
Anopheles mosquito, remains as one of the leading causes of
morbidity and mortality worldwide, particularly in Africa,
South-East Asia, and parts of South America [1]. When
infected mosquito feeds on a human, the infective form of
the Plasmodium parasite, sporozoites, is inoculated into the
dermis of the host. Most of the motile sporozoites then leave
the skin, travel through the blood circulation, and settle in
the hepatocytes. During this liver phase, sporozoites undergo
several asexual multiplications to form merozoites. Vesicles
containing mature merozoites, merosomes, are released into
the peripheral blood circulation and ruptured in the lungs
to release thousands of merozoites into the blood circula-
tion. These parasites infect red blood cells and initiate the
erythrocytic phase [2]. Due to the exponential growth of the
parasite, followed bymassive destruction of erythrocytes, this
stage is responsible for the common clinical manifestations of
malaria such as fever, headaches, chills, and diaphoresis [3].
Usually the host immune response can control and eliminate
the parasite, yet in some circumstance, patient’s conditions
deteriorate and develop severe systemic or organ-related
pathological conditions such as anemia [4], hypoglycemia,
febrile illness, respiratory distress [5], or cerebral malaria
(CM) [6].
2. Innate Immunity to Pathogens
For the past decades, it was shown that the host immune
response plays an important role in controlling the progres-
sion of malaria infection. The adaptive immunity, developed
through repetitive infections during childhood, is pivotal in
the elimination of Plasmodium parasite [7–10]. Yet, studies
suggest that the host’s ability to control the growth of parasites
also relies on the innate immunity [11, 12]. Recent analysis
of clinical records from neurosyphilis patients who under-
went malaria therapy showed a controlled parasite density,
irrespective of parasite strain, during the first and the second
parasite inoculation which suggested the presence of a stable
innate response [13]. In addition, peripheral blood mononu-
clear cells (PBMCs) from patients who had no prior exposure
to malaria were able to produce proinflammatory cytokines,
such as TNF-𝛼, IL-12, and IFN-𝛾, within 10 hours of expo-
sure to infected red blood cells (iRBCs) [14] demonstrating
the activation of innate immune response against malaria
parasite. However, proinflammatory cytokines are a double-
edged sword. Under normal circumstances, they are essential
for the control of parasite growth and sustained protection
against the disease pathology, yet excessive and dysregulated
production can lead to several immunopathologies [15, 16].
Human genetic diversity, parasite variability, and immune
status of host generate various disease profiles of malaria
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infections. Fortunately, only a fraction of malaria infection in
human leads to pathologies [17].This diversity in phenotypes
is always associated with differences in measured biological
and immune parameters. In addition, due to obvious ethnical
reasons, analyses of these parameters are largely confined to
peripheral blood (serum, plasma, and circulating cells). In
most studies, only association but not causal mechanisms
can be determined. Thus, malaria research mainly relies
on mouse models to investigate the host immune response
during malaria infection. Although these models cannot
reflect all aspects of human infections, they allow the study
of controlled experimental infections. There are 4 rodent
malaria species, P. berghei, P. chabaudi, P. vinckei, and P. yoelii,
13 subspecies, and various strains and cloned lines [18].These
parasites were isolated from African thicket rats in Central
and West Africa more than 50 years ago [19]. Depending on
the host and parasite combinations, different disease profiles
can be induced and host immune response will determine
the outcome of infection (Table 1). These models, when used
together with genetically deficient mice, allow in-depth study
on protection against infection or immunopathogenesis. For
example, the study of CM is hampered by the limited access to
tissue samples and difficulty to perform in vivo experiments.
Susceptible mice infected with P. berghei ANKA (PbA)
manifest neurological abnormalities similar to human CM.
In this model, termed experimental cerebral malaria (ECM),
high production of proinflammatory cytokines, sequestration
of parasite [20–23] and leukocytes, in particular CD8+ T
cells [24–26], and presentation of parasite antigen by brain
microvessels [27] lead to the damage of the blood-brain
barrier (BBB) and death. However, the role of innate immune
responses in this pathology still remains to be determined.
When pathogens breach the skin or mucosal barriers,
innate immune cells such as macrophages, mast cells, den-
dritic cells, and fibroblast, as well as circulating leukocytes,
including monocytes and neutrophils, sense foreign agent
using pattern recognition receptors (PRRs) that identify
conserved pathogen-associated molecular patterns (PAMPs)
on pathogens [28–30]. PRRs are either membrane-bound,
such as toll-like receptors (TLRs) [28, 31–33] and C-type
lectin receptors (CLRs) [28, 34–36], or free in the cytosol,
such as NOD-like receptors (NLRs) [37–39] and RIG-I-like
receptors (RLRs) [32, 40].These PRRs are distinctly expressed
on different cell populations which in turn influence the
immunological repertoire elicited by a particular antigen.
Professional antigen presenting cells, such as macrophage,
B cells [41, 42], and dendritic cells [41, 43, 44], are well
equipped with a wide spectrum of PRRs which enables this
surveillance team to recognize a great variety of PAMPs and
induce specific responses against each class of pathogens. For
instance, in human, myeloid dendritic cells (mDCs) express
all TLR1-10, but not TLR7, whereas plasmacytoid dendritic
cells (pDCs) exclusively express TLR7 and TLR9 [41, 43,
44]. When activated, mDCs preferentially induces IL-12
while pDCs mainly produces IFN-𝛼 [44]. Other PRRs, such
as dendritic cell-specific intracellular molecule-3-grabbing
nonintegrin (DC-SIGN) [45] and DNGR-1 (Clec9A) [46],
members of CLRs, expressed on immature DC were impli-
cated in tolerogenic responses in some studies [47–49].
Besides professional antigen presenting cells, some epithelial
cells are also furnished with PRRs. TLR2, TLR4, and TLR5
are widely found on pulmonary [50–53] and intestinal [54–
56] epithelial cells. Since these surfaces are in continuous
exposure to microbial challenges, strategic expression of
these TLRs on these surfaces enables prompt recognition
and response against bacterial infection. Vascular endothelial
cells that line the entire circulatory system express also TLR4
[57, 58], RIG-I [59], and NOD-1 [60].
Upon positive PAMPs recognition, PRRs trigger a cas-
cade of downstream signaling pathways that leads to nuclear
translocation of transcription factors such as nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-𝜅B),
activating protein-1 (AP-1), and interferon regulatory factors
(IRFs) into the nucleus.These transcription factors modulate
the production of inflammatory cytokines, chemokines, type
I interferon (IFN-I), and some interferon-stimulated genes
(ISGs) [127, 128], which in turn mobilize immune cells to
target pathogens and eliminate infections. Most of these
mechanisms have been identified for viral or bacterial infec-
tions [129, 130]. However, the precise mechanism by which
the innate immune receptors and their signaling trigger the
systemic inflammation and immune cells trafficking during
malaria infection has yet to be fully uncovered. Here, we
review the knowledge of the role of TLR-dependent and TLR-
independent pathways and the modulation of IRFs in the
activation of interferons (IFN) during malaria infection.
3. Recognition of Malarial Ligand by
Host Receptors
Malaria parasite travels undetected in the circulation as it
is encapsulated in the red blood cells. However, rupture of
the matured forms of infected red blood cells exposes the
parasite and releases malarial products which trigger host
immune response [131–133].This is evident by the paroxysms
of fever and chills which coincide with the time of schizonts
rupture [134]. The asexual erythrocytic stage of Plasmodium
life cycle begins when merozoites are released from infected
hepatocytes into the circulation. These merozoites infect red
blood cells for source of nutrients and possibly also as a
form of sanctuary from peripheral immune cells. Invasion is
initiated by the initial contact of the parasite with red blood
cells.Weak interactions of some glycosylphosphatidylinositol
membrane anchors (GPIs) on the surface of merozoites [135]
with receptors on red blood cells [136] trigger mechanisms
that further commit the parasite to invasion [137, 138]. During
invasion, most GPIs are shed from coat to facilitate entry into
the target cells [139, 140]. As the parasite multiples and feeds
on erythrocyte hemoglobin, it detoxifies hemoglobin heme
by-product intoHemozoin (Hz) which is kept in the digestive
vacuole (DV) [141–143]. Eventually, this DV, together with
leftover host hemoglobin, is discharged into the circulation
during egress of infective merozoites at the late schizonts
stage in an explosive manner [138, 144]. Throughout this
process of invasion and egress, the Plasmodium parasite
continually scattersmalarial products which could trigger the
immune system.
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Table 1: Combinations of different mouse backgrounds and parasite strains combinations allow the study of many disease profiles.











P. berghei ANKA-luc (231c11) [21, 77]
P. berghei ANKA-GFP [78, 79]
P. berghei ANKA clone 15cy1 [80, 81]
P. berghei ANKA-GFP clone 15cy1 [82]
P. berghei ANKA clone BdS [26, 83]
P. berghei ANKA sporozoite [73]
P. berghei ANKA clone 15cy1
sporozoite [80, 84]
C57BL/6
P. berghei K173 Protection from ECM [67]
P. yoelii nigeriensis N67C Lethal hyperparasitemia and severe anemia [85]
P. yoelii 17XNL
Protection from lethal hyperparasitemia and
severe anemia
[86]
P. yoelii yoelii 265 BY uncloned line [87]
P. yoelii nigeriensis N67 [85]
P. berghei NK65
Liver injury [88]
Malaria-associated acute respiratory distress
syndrome [76]
P. berghei NK65-GFP Placental malaria [89]
P. chabaudi chabaudi AS Protection in uncomplicated malaria [77, 90]
P. chabaudi AS [76, 91]
P. berghei ANKA-luc sporozoite
Liver-stage malaria [92]P. berghei NK65 sporozoite
P. yoelii 17XNL sporozoite
C57BL/6.C-H2 𝑑/bBy P. berghei ANKA-GFP sporozoite Liver-stage malaria [93]
CBA/J
P. berghei ANKA ECM [75]
P. yoelii 17X Protection from lethal hyperparasitemia and
severe anemia [94]P. yoelii 17XNL
CBA/T6 P. berghei ANKA ECM [95]P. berghei K173 Protection from ECM
CBA/CaH P. chabaudi adami 556 KA Protection against blood-stage malaria [96]
DBA/2 P. berghei ANKA Protection from ECM [84]Acute lung injury
129 Sv/Ev P. berghei ANKA clone 1.4 ECM [97]




[65, 70, 74, 75, 84]
P. berghei ANKA clone BdS [26]
P. berghei ANKA-GFP [79]
BALB/cByJ
SW
P. yoelii 17XL Lethal hyperparasitemia and severe anemia
[94]P. yoelii 17XNL Protection from lethal hyperparasitemia andsevere anemia
Extensive research has identified a few host recep-
tors agonists from Plasmodium parasite which promote
proinflammatory responses [61, 85, 99, 100, 102–106, 111,
112]. For the liver stage of the infection, Plasmodium RNA
is the only malarial ligand discovered so far [92]. In the
blood stage, several ligands have been identified, such as GPI
[62, 99–103], Hz [63, 104, 145], CpG DNA bound on Hz
[105], host fibrinogen [106], heme [107, 108], microparticles
[109], AT-rich motifs in malarial genome [61], Plasmod-
ium DNA/RNA [85], P. falciparum tyrosyl-tRNA synthetase
(PfTyrRS) [111], and P. falciparum high mobility group box
protein (PfHMGB) [112]. All the different malarial ligands
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Table 2: List of malarial ligands that stimulate different signaling molecules to trigger diverse immune responses and affect disease outcome
in various experimental models.
Ligand Signalling molecules involved Cell types/mice Immune responses/functions Ref.
GPI
TLR1-TLR2 heterodimer BMDM, PBMC
Stimulates production of TNF-𝛼,
IL-12, IL-6, and NO
[99]
TLR2/TLR1, TLR4, MyD88,
ERK1/2, p38, JNK1/2, NF-𝜅B,
AP-1 (c-Jun, ATF-2)
BMDM, PBMC, HEK, MPM [62, 100, 101]
MAPK2 BMDM Stimulates production of TNF-𝛼Controls production of IL-12 [102]
I𝜅B-𝜁 BMDM Involved in IL-12 expression [103]
Hz (Pf 3D7)/
synthetic Hz
TLR9, MyD88 Murine splenocytes, BMDDC
Stimulates production of TNF-𝛼,
IL-12p40, MCP-1, and IL-6 [104]
Knockout C57BL/6 or 129/Ola
x C57BL/6
Increases serum level of MCP-1 and
IL-6
TLR2, TLR9, MyD88 Knockout C57BL/6
Involved in ECM development
Promotes parasite and leukocyte
sequestration in brain sections




(Pf 3D7) TLR9, MyD88 BMDDC
Stimulates production of IL-12p40 and
Rantes [105]
Host fibrinogen TLR4, CD11b/CD18-integrin PBMC Stimulates release of ROS, TNF, andMCP-1 [106]




Stimulates production of TNF-𝛼 and
KC
Controls release of PGE2
[107, 108]
MPs from infected
mouse TLR4, MyD88 BMDM
Upregulate expression of CD40
Stimulate production of TNF [109]
Malarial AT-rich
motif STING, TBK1, IRF-3, IRF-7
BMDM, HEK293, knockout
C57BL/6
Involved in ECM development
Stimulates production of IFN-I,








Stimulates production of IFN-I
Controls parasitemia
Prevents parasite sequestration in the
brain capillaries and apoptosis in the
spleen




infection TLR2/4, MyD88 Knockout C57BL/6
Involved in ECM development
initiated with sporozoites
Partially involved in ECM
development initiated with iRBCs
Regulates production of IFN-𝛾,
MCP-1, TNF-𝛼, and IL-10
[80]
Unknown ligand in
Py 17XNL infection TLR9, MyD88 Knockout C57BL/6
Controls parasitemia and promotes
survival
Essential Th1 development and
cell-mediated immunity
Stimulates production of TNF-𝛼 and
IL-12 by DC
Controls production of IL-10 and IL-4
by DC
Induces cytotoxic activity in NK and
CD8+ T cells
[86]
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Table 2: Continued.
Ligand Signalling molecules involved Cell types/mice Immune responses/functions Ref.
Unknown TLR7, TLR9 NK cells, 𝛾𝛿 T cells, CD4
+ T
cells
TLR7 mediates IFN-𝛾 production by
NK cells 24 h after infection
TLR7 stimulates production of IFN-I,
IFN-𝛾, IL-10, and IL-12
TLR9 mediates IFN-𝛾 production by
CD4+ cells and stimulates production
of TNF 6 days after infection
[110]
Plasmodium RNA MDA5, MAVS, IRF-3, IRF-7 Knockout C57BL/6J,BMDDC, MPH
Stimulates production of IFN-I
Controls leukocyte recruitment which
limits parasite growth in the liver and
induction of erythrocytic stage
infection
[92]
PfTyrRs Unknown Mouse splenocytes, PBMC,RAW 264.7, THP-1
Stimulates production of TNF-𝛼, IL-6,
IL-1𝛼, and IL-1𝛽 which upregulate
expression of ICAM-1 and VCAM-1
receptors
[111]
PfHMGB Unknown Mouse splenocytes, RAW264.7
Stimulates production of TNF-𝛼, IL-6,
IL-8, and IL-1𝛽 and upregulates
mRNA expression of iNOS
[112]
BMDM:mouse bone marrow-derived macrophages (C57BL/6 unless otherwise stated); BMDDC: mouse bone marrow-derived dendritic cells; PBMC: human
peripheral blood mononuclear cells; HEK: human embryonic kidney epithelial cells; Hz: Hemozoin; iNOS: inducible nitric oxide synthetase; KC: keratinocyte
chemokine; MCP-1: monocyte chemoattractant protein-1; MP: microparticles; MPH: mouse primary hepatocytes; MPM: murine peritoneal macrophages;
PGE2: prostaglandin E2; PfTyrRS: P. falciparum tyrosyl-tRNA synthetase; PfHMGB: P. falciparum high mobility group box protein; RAW264.7: murine
macrophage-like cell line; ROS: reactive oxide species; THP-1: human monocytic leukemia cell line.
and their respective signaling molecules involved to induce
an immune response are listed in Table 2. However, the exact
roles of each of these factors remain to be established.
3.1. TLR-Dependent Signaling. TLRs are central in the sens-
ing and responding to pathogens during innate immunity.
Members of TLRs were originally identified in embryo of
Drosophila melanogaster more than 20 years ago [146]. Later,
Medzhitov et al. reported the first human homolog of the
Drosophila toll protein that is involved in the activation
of adaptive immunity [147]. To date, ten TLRs have been
identified in human and twelve in mice [148]. In both human
andmouse, TLRs 1, 2, 4, 5, and 6 are expressed on cell surface
whereas TLRs 3, 7, 8, and 9 are found within the endosomal
compartments. TLR10 is uniquely expressed in human [149]
and localized on the surface of plasma membrane. TLRs
11, 12, and 13 are only functionally expressed in mice and
expressed on the membrane of endosomes [150].These TLRs
recognize PAMPs ranging from DNA and RNA to bacterial
products [151]. Subcellular localization of TLR ensures that
different pathogenic antigens are promptly recognized by the
correct receptor in order to induce proper immune responses
and, at the same time, minimize accidental trigger of an
autoimmune response. Upon ligand-receptor interactions,
TLR signal transduction is initiated leading to production
of interferons and induction of proinflammatory cytokines
[31, 148, 151, 152].
3.1.1. TLR Polymorphism and Malaria. Studies on genetic
epidemiology revealed that TLR polymorphism is associated
with outcome of malaria infection (Table 3). A population
study in the Amazonian region of Brazil demonstrated that
single nucleotide polymorphisms in TLR1 and TLR6 are
associated with incidence of mild malaria [114]. Genetic
variations in TLR1 are also capable of influencing suscepti-
bility to placental malaria in Ghanaian mothers [113]. Case
control studies demonstrated that common polymorphism
in TLR2 and TLR4 can affect CM development [115, 119].
Variants in TLR2 amongst uncomplicated malaria children
in Uganda were associated with altered proinflammatory
responses [115] and a particular single nucleotide polymor-
phism in TLR4 amongst African children is correlated with
an altered responsiveness to the malarial ligand, GPI, which
in turn determine risk to severe malaria [119]. On the other
hand, another TLR4 variant assessed in Iran (Baluchi) [116],
Burundi [117], Brazil [114], and Ghana [118] was not found to
be involved in malaria infection or disease severity.
Effects of TLR9 polymorphism in malaria infection have
been most extensively studied amongst all the TLRs. Human
genetic studies in endemic regions found a strong correlation
in most of TLR9 variants with parasite load in the peripheral
circulation [114, 120]. However, association of TLR9 alleles
with susceptibility to malaria infection and disease severity
varies according to the single nucleotide polymorphism and
the regions studied [114, 116–121]. For example, TLR9 T1237C
rs5743836 was associated with susceptibility to malaria infec-
tion amongst people in Burundi but not in Ghana or Iran.
And amongst Ghanaians, susceptibility to mild malaria was
correlated with TLR9 T1486C rs187084, but not with TLR9
G2848A rs352140.
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Table 3: Association of TLRs and adaptor molecules gene polymorphisms with susceptibility to malaria or pathology in human.
TLRs/
adaptors SNPs Association Region Ref.
TLR1
S248N
rs4833095 Placental malaria and anemia Ghana [113]
I602S Susceptibility to malaria infection Amazon [114]
TLR2
Δ22
No association with serum cytokines (TNF, IFN-𝛾,
IL-1𝛽, IL-6, IL-10) levels
Uganda [115]Susceptibility to cerebral malaria
GT
𝑛
No association with serum cytokines (TNF, IFN-𝛾,
IL-1𝛽, IL-6, IL-10) levels




No association with susceptibility to malaria infection Burundi, Amazon,Ghana, Iran [114, 116–118]
No association with risk of placental malaria
Ghana [118]Maternal anemia
Severe malaria [119]
T399I No association with mild malaria Iran [116]
Severe malaria Ghana [119]




No association with susceptibility to malaria infection Burundi [117]
Susceptibility to mild malaria Ghana [120]
Level of parasitemia
No association with serum TNF𝛼 level
Uganda [121]No association with serum IFN-𝛾 level in mild malaria
children
Level of serum IFN-𝛾 level in CM children
T1237C
rs5743836
No association with susceptibility to malaria infection Ghana, Iran [116, 118, 120]
No association with disease severity Ghana [119]
No association with placental malaria [118]
Susceptibility to malaria infection Burundi [117]
Level of parasitemia Amazon, Ghana [114, 120]
No association with serum TNF𝛼 level
Uganda [121]No association with serum IFN-𝛾 level in mild malaria
children
Level of serum IFN-𝛾 level in CM children
T1486C
rs187084
No association with susceptibility to malaria infection Burundi, Ghana, Iran [116–118, 120]
No association with disease severity
Ghana
[119]
No association with placental malaria [118]
No association with level of parasitemia [120]
Level of parasitemia Amazon [114]
G2848A
rs352140
No association with level of parasitemia Ghana [120]
Susceptibility to mild malaria infection
TIRAP S180Lrs8177374
No association with susceptibility to malaria or severity
of infection Burundi, Amazon [114, 117]
Mild malaria and severe malaria Gambia,Vietnam, Kenya [122]
Mild malaria Iran [116]
CM: cerebral malaria; Δ22: 22 base pair deletion in the first untranslated exon; GT
𝑛
: GT dinucleotide repeat in the second intron; mild malaria: patients suffer
fever with temperature greater than or equal to 38∘C, malaise, muscular pain, headache, and parasite load greater than or equal to 5000 parasite/ul of blood;
severemalaria: patients who suffer anaemia, prostration, respiratory distress, convulsions, and/or impaired consciousness; cerebral malaria (CM): patients who
experience coma with P. falciparum on blood smear and have no other cause for coma.
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Besides TLR, effects of single nucleotide polymorphism
of coadaptor molecule, TIR domain-containing adaptor pro-
tein, TIRAP, on malaria infection were also investigated. A
particular TIRAP variant was correlated with mild malaria
amongst people living in Iran [116], Gambia, Vietnam,
and Kenya [122]. However, when the same TIRAP alleles
were sampled in Burundi and Amazon, no association with
susceptibility to malaria or disease severity was observed
[114, 117]. These findings suggest that variants in TLR are
capable of altering disease outcome during malaria infection
but polymorphism in the strains of Plasmodium in different
regions could also account for the different association.
3.1.2. TLR in Malaria Infection. Purified GPI from P.
falciparum iRBCs [153] was preferentially recognized by
TLR2/TLR1 or TLR2/TLR6 heterodimer and, to a lesser
extent, TLR4 in vitro [99, 101]. TLRs-GPI interactions trig-
ger the recruitment of MyD88, which phosphorylates a
series of mitogen-activated protein kinases (MAPKs) includ-
ing extracellular-signal-regulated kinases 1/2 (ERK1/2), p38
MAPK, and c-Jun N-terminal kinases 1/2 (JNK1/2) [62, 100,
101]. Following that, nuclear translocations of transcription
factor such as NF-𝜅B and AP-1, comprising the activation of
transcription factor-2/c-Jun (ATF-2/c-Jun) [100, 102], stimu-
late production of proinflammatory cytokines such as TNF-𝛼,
IL-6, IL-12, and nitric oxide (NO) [100, 102, 154]. Interaction
of nuclear factor of kappa light polypeptide gene enhancer
in B cells inhibitor, zeta (I𝜅B-𝜁) with NF-kB, promotes IL-
12 production [103]. However, the concentration of GPI on
the surface of merozoites is too low to account for this potent
stimulatory effect observed [155].
A study by Pichyangkul et al. described an unknown, heat
labile, malarial product in the schizont-soluble fraction that
is able to upregulate expression of CD86 and stimulate IFN-
𝛼 production by human plasmacytoid dendritic cells. When
mouse bone marrow-derived dendritic cells (BMDDC) were
stimulated with the same schizont fraction, upregulated
expressions of CD40, CD86, and IL-12 production were
observed [156]. Later, this ligand was proposed to be a
metabolic by-product, Hemozoin (Hz), that is present in P.
falciparum schizont lysate [157]. It is recognized by TLR9
to induce production of proinflammatory cytokines such
as TNF-𝛼, IL-12p40, MCP-1, and IL-6 [104]. However, this
discovery was refuted by Parroche et al. who suggested
that Hz only serves as a vehicle to deliver the malarial
DNA, a TLR9 ligand, to the endosome for TLR9 sensing
[105]. Similarly, Barrera et al. also supported the claim that
Hz is only a vehicle for other malarial ligands, such as
host fibrinogen. In this case, instead of TLR9, TLR4 and
CD11b/CD18-integrin on monocytes were shown to recog-
nize these malarial ligands [106]. In response to these, Coban
et al. have recently demonstrated that both DNase-treated
natural Hz and synthetic Hz are recognized by TLR9 and able
to elicit an immune response via MyD88 [145]. These highly
discordant results are likely due to different methodologies
adopted by each group to purify the malarial Hz. Parroche
et al. and Sharma et al. purified free Hz biocrystals using
a magnetic separator [61, 105], whereas both Barrera et al.
and Coban et al. utilized different protocols that largely
consist of various chemical and mechanical procedures to
obtain the natural Hz [104]. Despite disagreement on the
ligand that stimulates the immune response, in vitro studies
by both Parroche et al. and Coban et al. agreed upon the
importance of TLR9 in P. falciparum infection. During P.
falciparum infection, activation of TLR9mediates production
of IL-12 and IFN-𝛾.These proinflammatory cytokines in turn
enhance expression of TLR and prime the signaling pathway
to be more sensitive to TLR agonist [158].
Heme is released into the circulation when cell-free
hemoglobin, from ruptured schizonts, is oxidized by reactive
oxygen species (ROS) or other free radicals present in the
plasma. The prosthetic group is recognized by TLR4, along
with coreceptor CD14 [107, 108]. This interaction triggers
MyD88 recruitment, I𝜅B𝛼 degradation, ERK1/2 phosphory-
lation, and eventually NF-𝜅B activation. Endotoxin contam-
ination was abolished through the use of polymyxin B, anti-
TLR4/MD2, and lipid A antagonist which inhibit effect of
lipopolysaccharide (LPS) [108]. A study on a population of
P. vivax-infected Brazilians discovered a correlation between
high concentrations of heme in the plasma with disease
severity. This is mediated through the activation of antiox-
idant enzyme Cu/Zn superoxide dismutase (SOD-1) which
impairs production of anti-inflammatory mediators, such as
Prostaglandin E2 (PGE
2
) and TGF-𝛽, by PBMCs [107]. In
the same study, plasma level of proinflammatory cytokine,
TNF-𝛼, was found to be positively correlated with total heme
and SOD-1 [107]. Heme can be detrimental in other ways
such as its toxic effects on endothelial cells [159–161] and
hepatocytes [162]. At the same time, it promotes survival
[163], activation [164], and migration [165] of polymorph
nuclear cells. Taken together, it seems to suggest that free
heme in the plasma could engage in multiple signaling
pathways to promote a proinflammatory immune response,
which possibly exacerbates the malaria infection.
Microparticles (MPs) are submicron vesicles produced
through membrane budding during immune-activation or
cell death. Extensive studies revealed that MPs are capable
of influencing biological functions such as expression of
adhesion molecules by endothelial cells [166] and leukocyte
recruitment [167]. In addition, these minute vesicles also
play a part in pathology, for instance, by inducing nitric
oxide synthesis [168, 169] and delivering mRNA into other
cells [170, 171]. During malaria infection, MP derived from
iRBCs affects disease progression by strongly inducing bone
marrow-derived macrophages (BMDM) to produce TNF
[109, 172]. In vitro study revealed that MP, and not LPS
contamination, engages in a TLR4-MyD88 signaling pathway
to induce this immune response. Since MP could contain
other parasite proteins, like GPI andHz, in the vesicles, it was
not surprising that both TLR2 and TLR9 were also found to
be involved in the induction of this MP-mediated signaling
pathway. In fact, synergic engagement of all these TLRs with
MP and other parasite ligands stimulated a proinflammatory
response stronger than that induced by iRBCs [109].
The TLR signaling pathway is also involved in the devel-
opment of placental malaria [89]. Study of P. berghei NK65-
induced placental malaria in mice showed that MyD88 is
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essential in the production of proinflammatory cytokines
such as IL-6, IFN-𝛾, and TNF-𝛼. In addition, the MyD88
pathway also affects the survival rates of pups from malaria-
infected mothers [89]. Unfortunately, no specific TLR or
malarial ligands were identified to account for the activation
of this MyD88 signaling pathway.
3.1.3. TLR in ECM. Optimal production of proinflam-
matory cytokines can control parasite growth but over-
whelming secretion of these soluble mediators can lead
to immunopathologies such as cerebral malaria. Human
population studies have demonstrated that single nucleotide
polymorphism in TLRs can affect susceptibility to cerebral
malaria [113–121]. However, no exact mechanism can be
derived from such studies. Using the murine model of ECM,
specific immune responses upon TLR-ligand interactions can
be studied.
TLR2/TLR4, which recognizes malarial GPI, despite
playing no role in the early stage of P. chabaudi infection
(IFN-I secretion in this model is mediated by TLR7) [110],
is important in ECM. The absence of these receptors leads
to an attenuated proinflammatory response and protection
from ECM lethality [63, 80]. However, different model seems
to display varying degrees of reliance on this signaling
pathway to induce ECM. Using wild-type (WT) and TLR2-
knockout (KO) or MyD88-KO in C57BL/6 background
mice infected with 106 fresh PbAiRBCs intraperitoneally,
Coban et al. [63] showed that ECM pathogenesis totally
relies on TLR2-MyD88 signaling pathway. Activation of this
pathway led to sequestration of parasites and infiltration
of pathogenic T cells into the brain, two important factors
responsible for damaging the brain endothelial cells. On the
contrary, in this model, TLR4 was shown not to be involved
in ECM development. Conversely, Kordes et al. showed
that WT and TLR2/4 double knockout (DKO) in C57BL/6
background mice, infected with 104 fresh PbA(clone 15cy1)
iRBCs intravenously, trigger a proinflammatory response
that is partially dependent on TLR2/4-MyD88 signaling
pathway to cause ECM [80]. Unlike blood-stage infection,
intravenous inoculation of PbA (clone 15cy1) sporozoites has
absolute dependence onMyD88-dependent TLR2/4 pathway
to develop ECM [80]. Inconsistency in the involvement of
TLR2/4 in thesemodels could be attributed to different infec-
tion regimens or the parasite strain/clones used. In a separate
study, it was revealed that heme engages with TLR4-MyD88
signaling pathway to secrete TNF-𝛼 in mouse peritoneal
macrophages and BMDDC. In fact, heme can also engage in
a TLR4-independent pathway to induce production of ROS,
expression of heme oxygenase-1 (HO-1), and recruitment of
neutrophils [108]. Besides TLR2/4, TLR9 is also shown to
play a role in ECM [63]. Coban et al. demonstrated that ECM
pathogenesis relied on TLR9-MyD88 signaling to induce
systemic proinflammatory responses and sequestration of
parasite, Hz, and leukocytes in the brain [63].
In addition, TLR9was discovered to work in synergywith
TLR7 to induce IFN-I and IFN-𝛾 production inmice infected
with many other strains of Plasmodium, like P. chabaudi,
P. berghei NK65, P. berghei K173, P. yoelii YM (PyYM), P.
yoelii 17X (Py17X), and P. vinckei petteri infection [90, 110].
C57BL/6 mice infected with Py17XNL were shown to rely
on TLR9-MyD88 signaling pathway to induce production of
proinflammatory cytokine and increase commitment to Th1
and cytolytic activity by NK and T cells [86].
Despite all these findings that supported the involve-
ment of TLR2/TLR4/TLR9 in ECM development, Lepenies
et al. held a different opinion. Using triple TLR2/4/9 KO
mice on C57BL/6 mice, intraperitoneally inoculated with
PbA iRBCs that was maintained through alternate cyclic
passage in Anopheles stephensi mosquito and BALB/c mice,
they demonstrated that ECM induction is independent of
TLR2/4/9 [64]. Such disparity in research findings could be
due to the uniquemaintenance of parasite strain/clones used.
Similarly, in spite of all these studies that demonstrated the
importance of TLR, the study by Togbe et al. [78] casts some
doubt on the importance of TLR cascade in the development
of ECM. In his study, C57BL/6 mice were infected with a
cloned line of PbA tagged with GFP. Results showed that
deficiency in TLR did not prevent development in ECM,
lungs, or liver pathology. Once again, these conflicting results
emphasized the diversity of the immune response to malaria
infection in different animal models [65].
3.2. TLR-Independent Signaling. In the erythrocytic stage,
AT-rich motifs in the P. falciparum genome can also induce
secretion of IFN-I, TNF-𝛼, IL-6, and IL-15 via a TLR-
independent pathway. This ligand engages in a distinct
signaling pathway that involves cytoplasmic nucleic sensor
STING, downstream kinase TBK1, and interferon regulatory
factor (IRF) 3/7 [61]. Besides, PfTyrRS [111] and PfHMGB
[112] are two othermalarial ligands that were shown to induce
proinflammatory activity. However, more studies are needed
to identify the specific receptors that recognize these two
ligands. Other cytoplasmic signaling molecules, such as the
member of RLR family and its adaptor molecule, melanoma
differentiation-associated protein 5/mitochondrial antiviral
signaling protein (MDA5/MAVS), were also associated with
IFN-I signaling during acute phase of nonlethal P. yoelii
nigeriensis N67 (PyN N67) infection in C57BL/6 mice [85].
On the contrary, STING and MAVS were found to be
redundant in early P. chabaudi infection [110] and P. yoelii
liver-stage infection [126].
Host innate immune response does not only exist in the
erythrocytic stage of the parasite life cycle. In fact, control
of parasitic growth starts as early as in the asymptomatic
liver stage [173, 174]. Liver resident cells of C57BL/6 and
BALB/c mice were shown to induce IFN-I production upon
infection with PbA or Py17XNL sporozoite, independent
of TLR-MyD88 pathway [92]. The Plasmodium RNA was
found to be identified by MDA5, which typically recognizes
double stranded DNA. This triggers the assembly of MAVS,
which mediates downstream production of IFN-I. Liver-
stage specific IFN-I mobilizes leukocytes into the vicinity of
infected hepatocytes to limit parasite load in the liver and
consequently influences the induction of erythrocytic stage
infection. Besides MDA5, there are other unknown malarial
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ligands that signal throughMavs as evident by the differential
IFN-I response in MDA5−/− and MAVS−/− mice [92].
4. Interferons
Recognition of PAMPs by PRRs triggers a cascade of down-
stream signaling pathways which stimulates production of
IFN-I, IFN-𝛾, and many other proinflammatory mediators.
The IFN compartment comprises 3 classes, namely, IFN-I,
IFN-II, and IFN-III. IFN are renowned for their antiviral
properties and share common secondary structure. Yet each
class of IFN binds to distinct multichain receptor complexes.
They engage in different JAK-STAT molecules, drive the
expression of different interferon stimulated response ele-
ments (ISRE) and/or interferon-gamma activated sequences
(GAS) elements [175], and induce various interferon stimu-
lated genes (ISGs), which in turn regulate development, host
defense, and signaling [176]. In humans and mice, the IFN-I
family comprises 13 types of IFN-𝛼 and 1 IFN-𝛽 [177]. IFN-II
consists of solely interferon gamma (IFN-𝛾), while there are
3 types of IFN-III, namely, IFN𝜆1, IFN𝜆2, and IFN𝜆3 [175].
4.1. Type II Interferon (IFN-𝛾). IFN-𝛾 is the only form of type
II IFN. It regulates several components of the immune system
such as antigen presentation [178–181], antimicrobial mecha-
nism [182–184], leukocyte development [185], and immune
cells trafficking [186, 187]. It is the most widely studied
interferon in malaria infection since it is primarily involved
in host defense against intracellular pathogens. Its protective
role as an immune mediator emerged as early as in the liver
stage [126, 188–193]. In vitro study of human recombinant
IFN-𝛾 treatment on P. berghei sporozoites-infected murine
hepatocytes [190] or humanhepatoma cells [189] identified an
inhibitory effect of IFN-𝛾 on parasite multiplication. Further
in vivo study validated the importance of IFN-𝛾 in protective
immunity as it inhibits intracellular development of parasite
within hepatocytes following challenge with P. berghei [194],
P. yoelii [191], or P. vivax sporozoites [188] in mice and chim-
panzee, respectively. Recently, Miller et al. demonstrated that
IFN-𝛾 secreted in primary P. yoelii sporozoite infection is the
key innate mediator that controls liver-stage parasite growth
in a secondary infection [126]. Above all, this inhibitory effect
of IFN-𝛾 on parasite development in liver stage extends and
influences the initiation of blood stage parasite growth [126].
IFN-𝛾 also plays a crucial protective role during blood-
stage infection of various parasite strains. Administration of
exogenous recombinant IFN-𝛾 leads to control of parasite
growth in P. chabaudi adami 556KA-infected CBA/CaH
mice. After infection has been resolved, continuous IFN-
𝛾 treatment fully protected these mice from subsequent
infection [96]. Lower level of parasitemia was also observed
in IFN-𝛾 treated SWmice that were infectedwith lethal strain
of P. yoelii. In addition, these treated mice also exhibited
better survival outcome [94]. P. chabaudi AS-infected mice
treated with monoclonal antibody against IFN-𝛾 had less
control of parasitemultiplication [195], once again suggesting
that IFN-𝛾 is essential for limiting parasite growth. Similar
findings were observed in P. chabaudi AS-infected mice that
were deficient in IFN-𝛾 receptor. However, these mice had
lower survival rates as compared to theWT controls [91].This
suggests that IFN-𝛾 production at different period during
infection could alter survival outcome. In P. berghei infection,
IFN-𝛾 also plays a protective role by mediating parasite
clearance [196]. Population study of children in Papua New
Guinea showed that high and early IFN-𝛾 responses seem to
protect from symptomatic malaria [197].
However, production of high level of IFN-𝛾 during
parasite blood stage development is associatedwith predispo-
sition to severe malaria, such as CM. Studies in animal model
of ECM corroborated findings from human study that IFN-𝛾
is essential for the development of CM [66]. IFN-𝛾 signaling
in the brain regulates expression of adhesionmoleculeswhich
influence parasites and leukocytes sequestration in the brain
microvessels [97]. At the same time, there is also evidence
that IFN-𝛾 promotes trafficking of leukocytes, including
pathogenic CD8+ T cells, to the brain [81, 83]. IFN-𝛾 is
essential in both protective immunity and pathogenesis of
severe diseases [198]. Whether it protects or harms the host
depends on when and where it is produced [67].
4.2. Type I Interferon (IFN-𝛼/𝛽). Unlike IFN-𝛾, IFN-I is only
starting to gain more attention with increasing evidence
that supports its role in protection [87, 199, 200]. This
cytokine regulates various immune mechanisms such as
MHC expression [201], antigen presentation [201], and T cell
expansion [202, 203]. Furthermore, IFN-I can also modu-
late production of IFN-𝛾 [204] and prime IFN-𝛾-mediated
immune responses [205]. The earliest report which revealed
its significance in malaria demonstrated that exogenous
administration of unpurified mouse serum IFN was able
to protect CF-1 mice from PbA sporozoite infection [206].
Although the experiment suggested a role for IFN-Ι, this
unpurified mouse serum contains mediators other than IFN-
Ι [207], such as IL-6, which have activity against Plasmodium
liver stages [208]. Following that, a study of treatment with
recombinant human IFN-𝛼, which cross-reacts with mouse
cells, did not show any effect on near matured (42 h) liver
stage after a challenge with P. yoelii sporozoite [87]. However,
recent analysis of liver transcriptome obtained from PbA
[92] or Py [92, 126] sporozoite-infected C57BL/6 or BALB/c
mice revealed an upregulation of genes expressions that are
linked to IFN signaling. IFN-Ι was found to act during the
very late phase of the liver stage and this liver specific IFN-
Ι production partially limits parasite growth in the liver and
influences initiation of erythrocytic stage infection [92]. In
mice, P. yoelii and P. berghei liver stages last a minimum
of 48 h and 51 h, respectively [209], and the effect of IFN-
Ι was only apparent after 48 h but not 42 h after sporozoite
infection. Interestingly, the IFN-Ι effect was indirect and
mainly mediates the recruitment of leukocytes around liver-
stage parasites. IFN-𝛾-secreting immune cells, in particular
CD1d-restricted NKT cells, are the main players responsible
for the innate elimination of liver stage [126]. Leukocyte-
mediated inhibition of liver-stage parasite further leads to a
reduced development of parasitemia [92]. More importantly,
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this innate immune response can facilitate parasite elimina-
tion in subsequent liver-stage infection [126, 191]. In fact, early
production of ΙFN-I prior to infection can impair parasite
establishment [92].
Compared to liver-stage infection, ΙFN-Ι has a more
striking role against blood stage parasites. Previous work
shows that treatment ofC57BL/6micewith pure recombinant
IFN-𝛼 inhibits P. yoelii or P. berghei blood stage development
[87]. This effect was indirect and mediated by IFN-𝛾 [210].
During early stage of P. chabaudi infection, IFN-I induced by
the infection plays a pathogenic role by suppressing IFN-𝛾
producing CD4+ T cells that control parasite load in C57BL/6
[77] but not in 129 Sv/Ev mice [98]. These results are not
contradictory but suggest different levels of IFN-I and the
duration of action is essential for proper immune response
to control parasite growth.
In human, polymorphism in the receptor of IFN-I,
IFNAR, has been shown to be robustly associated with
progression of CM [79, 200]. It was further revealed that
peripheral blood mononuclear cells fromMalawian children
recovering from severe malaria had higher expression of
genes involved in interferon pathway [211]. In murine model,
recombinant IFN-𝛼 [210] or IFN-𝛽 [68] treatment protected
mice from ECM death. When PbA-infected C57BL/6J mice
were administeredwith recombinant human IFN𝛼, increased
level of IFN-𝛾 in treatedmice was observed, whichwas linked
to improved control of parasitemia and survival [210]. On
the other hand, IFN-𝛽 treatment prevented ECM death by
suppressing the expression of chemokine receptor CXCR3,
the production of IFN-𝛾, and chemokine ligand CXCL9.
Consequently, decreased T cells migrate and sequester in the
brain thereby preserving a better vascular integrity of blood
brain barrier as compared to nontreated WT controls [68].
However, IFN-I induced endogenously during Plasmodium
infection plays a pathogenic role in ECM development.
Absence of IFN-I signaling, in mice deficient in IFNAR,
either delayed [82] or fully protected [77, 79] the mice
from ECM. Haque et al. [77] attributed this protection to a
restrained parasite growth in the absence of IFN-I pathway
whereas Ball et al. [79] and Palomo et al. [82] concluded
that deficiency in IFN-I signaling reduced sequestration of
pathogenic T cells in the brain. All these conflicting data
suggest that effects of IFN-I might rely on precise level and
timing of expression of systemic IFN-I.
5. Interferon Regulatory Factors
Both IFN-I and IFN-𝛾 are essential in the immune response
against malaria infection. Production of IFNs is triggered
upon recognition ofmalaria antigen by receptors as discussed
above. Although an array of receptors and downstream
signaling molecules have been implicated, all signaling path-
ways ultimately converge to a few downstream transcription
factors, such as IRFs, which regulate gene expression of IFNs.
The family of IRFs comprised 9 members, namely, IRF1-9.
Each IRF binds to a unique set of ISRE to stimulate tran-
scription of diverse genes that are translated into functional
proteins [212, 213]. The diverse roles of a few IRFs in malaria
infection have been uncovered recently (Table 4).
5.1. Interferon Regulatory Factor 1. The first member of the
IRF family identified that binds to the promoter region of
IFN-𝛽 gene is IRF-1. This transcription factor is expressed
in many cells types. It mediates signaling of both IFN-I and
particularly IFN-𝛾, a strong inducer of IRF-1 expression.
IRF-1 regulates antigen presentation, monocyte/macrophage
differentiation, T cell development, and B cell growth [214]
and promotes Th1 response [215]. In humans, the IRF-1 gene
is located in chromosome 5q31-33 region and variation in
5q31-33 region was associated with variations in parasite
density during P. falciparum erythrocytic infection [216]. A
subsequent study in West African ethnic groups identified
that polymorphisms in IRF-1 gene could lead to differential
abilities to control P. falciparum infection [123]. Despite the
fact thatMangano et al. discovered a correlation between IRF-
1 and control of P. falciparum infection [123], they found no
association of this transcription factor in the development
of severe malaria pathology amongst African children [124].
Using mice deficient in IRF-1, Tan et al. showed that IRF-1
is essential in limiting parasite growth and survival outcome
of PbA infection [125]. Further animal studies also demon-
strated that IRF-1 regulates antigen presentation [214] and is
indispensable in the pathogenesis of ECM. When infected
with PbA, mice deficient in IRF1 were partially protected
from ECM with a lesser control in parasite growth in the
circulation [69]. Microarray analysis of brains from ECM-
susceptible C57BL/6 mice as compared to ECM-resistant
BALB/c mice revealed an increase of IRF-1 gene expression
[70]. Similarly, IRF-1 gene expression was higher in brain
from CBA/T6 mice infected with ECM-causing PbA parasite
than with non-ECM causing P. berghei K173 parasite [95].
With this evidence, there is a need to further investigate
the exact implication of IRF-1 in these different immune
mechanisms which are essential for ECM pathogenesis [27].
Recently, Wu et al. also demonstrated that higher expres-
sion of IRF-1 gene and production of IFN-I enabled better
control of parasitemia in nonlethalP. yoeliiN67-infectedmice
than in lethal P. yoelii N67C-infected mice [85]. However,
the role of IRF-1 in IFN-𝛽 signaling remains controversial
as stimulation of splenocytes from IRF-1 deficient mice
with malarial genome-alike AT-rich oligonucleotides did not
abrogate IFN-𝛽 production [61]. This discrepancy could be
due to the use of different malaria ligand to induce IFN-
I production comforting previous speculation of multiple
signaling pathway to produce IFN-I [217].
5.2. Interferon Regulatory Factor 3/7. Among the 9 IRFs,
IRF-3 and IRF-7 are the master regulators of IFN-I. They
are responsible for driving the initial transcription of IFN-
I during early stage of infection. Induction of IFN-I is
generated through a biphasic mechanism which warrants
transcriptional efficiency and diversity of targeted genes. IRF-
3 is constitutively expressed in the cytoplasm of all cells and
resides as an inactive form. Upon phosphorylation, activated
IRF-3 translocates into the nucleus and forms enhanceosome
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Table 4: Diverse roles of different IRFs in malaria infection.
Host
/model Infection Functions Ref.
IRF-1
Human P. falciparum Controls parasitemia [123]
Not involved in development of severe malaria [124]
Mice
Py nigeriensis N67 iRBCs Plays a role in IFN-I signaling [85]
PbA iRBCs
Involved in ECM development
Controls parasitemia [69]
Involved in ECM development
Promotes parasitemia [125]
Regulates production of IFN-𝛾 and IL12p4
Controls CD8+ T cells numbers [72]
Plays a role in ECM development [70, 95]
Ex vivo AT-rich oligonucleotides No effect on IFN-𝛽 production by splenocytes [61]
IRF-3 Mice
P. yoelii sporozoite Mediates IFN-I-induced innate response duringliver-stage infection [126]
P. chabaudi iRBCs
Mediates splenic IFN-𝛼, but not IFN-𝛽, transcription in
red pulp macrophages [90]
Not involved in IFN-I production [110]
IRF-5 Ex vivo AT-rich oligonucleotides Not involved in IFN-𝛽 production by splenocytes [61]
IRF-7 Mice
Py nigeriensis N67 iRBCs Plays a role in IFN-I signaling [85]
PbA iRBCs Plays a role in ECM development [70, 71]
P.chabaudi iRBCs
Mediates splenic IFN-I transcription in red pulp
macrophages [90]
Involved in IFN-I production [110]
IRF-3 and IRF-7
Mice PbA sporozoite
Mediate IFN-I response in liver-stage infection
Control parasite load in the liver [92]
PbA iRBCs Involved in ECM development
[61]Ex vivo AT-rich oligonucleotides Mediate IFN-𝛽 production by splenocytes
Pf iRBCs Mediate IFN-𝛽 production by macrophages
IRF-8 Mice PbA iRBCs
Plays a role in ECM development [95]
Regulates production of proinflammatory cytokines
Mediates IFN-I production
Controls antigen processing and presentation and
chemotaxis
[72]
IRF-9 Mice Py nigeriensis N67 iRBCs Plays a role in IFN-I signaling [85]
PbA iRBCs Plays a role in ECM development [72]
with other transcription factors, namely, NF-kB and AP-
1 [218], which will lead to IFN-𝛽 transcription [219–221].
On the other hand, IRF-7 is expressed at very low levels
in the cytoplasm of most cells. Positive feedback of IFN-𝛽
increases IRF-7 expression. Like IRF-3, it undergoes nuclear
translocation and forms heterodimer with IRF-3 to bind with
ISRE. Unlike IRF3, IRF-7 induces maximal transcription of
both IFN-𝛼 and IFN-𝛽 [222]. The role of IRF-3 and IRF-7 in
malaria infection remains poorly defined.
When mice deficient in either IRF-3 or IRF-7 were
infected with PbA sporozoite, significant impairment in
IFN-I response was observed. Consequently, these deficient
mice had higher parasite load in the liver and peripheral
circulation as compared to their WT counterparts. Initia-
tion of blood-stage infection was also found to be 1-day
earlier in the KO as compared to WT mice [92]. On the
other hand, only mice deficient in IRF-3 displayed marked
impairment in the control of parasite burden in the liver
upon secondary P. yoelii sporozoite infection [126]. Such
disparity could be attributed to the strain of parasite or the
time point measured in each study. Since IRF-3 stimulates
IFN-𝛽 production [219–221] and IRF-7 induces both IFN-
𝛼 and IFN-𝛽 production [222], the significance of IRFs in
each infection model could possibly hint on the importance
of IFN-𝛼 and/or IFN-𝛽 at different window of the liver-
stage infection. When stimulated with infected red blood
cells or AT-rich motif derived from genome of P. falciparum,
splenocytes obtained from mice deficient in both IRF-3 and
IRF-7 had attenuated IFN-𝛽 production, demonstrating a
role for one or both of these factors in IFN-𝛽 production [61].














































































Figure 1: (a) Signaling pathway induced bymalarial ligand during liver-stage infection. PlasmodiumRNA is recognized byMDA5 (melanoma
differentiation-association protein 5) present in the cytoplasm. Ligand-receptor interaction triggers assembly of MAVS (mitochondrial
antiviral signaling protein) that aggregate on the surface ofmitochondria.This eventually leads to the activation of both IRF-3 and IRF-7which
regulate transcription of IFN-I. Besides MDA5, activation of other receptors can also trigger aggregation of MAVS. However, this specific
receptor and its correspondingmalarial ligand have yet to be identified. (b) Signaling pathway induced bymalarial ligand during erythrocytic-
stage infection. Surface TLR4 recognizes a number of malarial ligands such as GPI (glycosylphosphatidylinositol membrane anchor) andMP
(microparticles). Together withCD14 orCD11b/CD18 integrin, it can recognize heme and host fibrinogen, respectively. Both TLRheterodimer
TLR1/TLR2 and TLR2/TLR6 recognize GPI.Within the endosomal compartment, Hz (Hemozoin) and CpGDNA are recognized by TLR9. In
addition, TLR7/TLR9 heterodimer has been proposed to recognize an unknownmalarial ligand.These ligand-receptor interactions trigger 3
proposed pathways. (1) TLR-dependent pathway involves the recruitment ofMyD88 (myeloid differentiation primary gene 88) to TLR, which
phosphorylates downstream MAPKs (mitogen-activating protein kinases), such as ERK1/2 (extracellular-signal-regulated kinases 1/2), p38
MAPK, and JNK1/2 (c-Jun N-terminal kinases 1/2). Subsequently, NF-𝜅B (nuclear factor kappa-light-chain-enhancer of activated B cells)
and AP-1 (activating protein-1) translocate into the nucleus and stimulate production of proinflammatory cytokines. At the same time,
phosphorylated MAPKs or MyD88 can induce activation of IRF-3 and IRF-7 to transcribe IFN-I and ISGs (interferon stimulated genes).
(2) Activation of TLR-independent pathway triggered by AT-rich motif present in the plasmodial genome engages STING, TBK, IRF-3, and
IRF-7. (3) Another TLR-independent pathway involves MDA5 and MAVS. PfTyrRS (P. falciparum tyrosyl-tRNA synthetase) and PfHMGB
(P. falciparum high mobility group box protein) were shown to induce proinflammatory responses but the exact signaling pathways have yet
to be identified.
In mice infected with P. chabaudi, early IFN-𝛼 production by
red pulp macrophages is dependent on both IRF-3 and IRF-7.
Intriguingly, contrary to what is observed with viruses [223–
226], IFN-𝛽 production was independent of IRF-3 [90, 110],
suggesting an alternate pathway of activation for malaria
parasite. Microarray analysis of brain from ECM-susceptible
mice showed a higher transcriptional activity of IRF-7 than
ECM-resistant [70] and uninfected control mice [71]. Double
IRF-3/IRF-7 deficient mice infected with PbA were resistant
to ECM upon infection [61] confirming a role for IFN-I in
ECM. However, the precise functions of IRF-3 and IRF-7 in
CM remained to be determined.
5.3. Interferon Regulatory Factor 8. IRF-8 is one of the unique
IRFs that is only expressed in immune cells [227]. Unlike
IRF-3 and IRF-7, expression of IRF-8 is induced by IFN-𝛾
instead of IFN-I.This transcription factor coordinates growth
and differentiation of myeloid cells, such as macrophages
and dendritic cells, and production of proinflammatory
cytokines, such as IFN-I and IL-12p40 [227]. Together with
IRF-1 [228], IRF-8 directs transcription programs in immune
cells towards a Th1-dominated response [229]. Since ECM
is a Th1-mediated pathology [230–232], it is not surprising
that amplification in IRF-8 gene expression was observed in
the brains of ECM-susceptible PbA-infected CBA/T6 mice
[95]. Mice with dysfunctional IRF-8 are protected from ECM
due to downregulated transcriptional activity of many IRF-8-
dependent genes which are essential in various aspects of the
immune response during PbA infection. These modulated
genes are involved in antigen processing and presentation,
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chemotaxis, maturation of phagosomes, and production of
proinflammatory cytokines [72]. Though both reports con-
curred that IRF-8 is involved in ECM development, further
research is mandatory to ascertain its role in human CM.
5.4. Other Interferon Regulatory Factors. Apart from IRF-
1, IRF-3, IRF-7, and IRF-8, some studies have also briefly
explored the role of IRF-5 and IRF-9 in malaria infection.
IRF-5 is expressed in B cells and dendritic cells. Like IRF-
7, it is mainly regulated by IFN-I. This transcription factor
interacts with IRF-1, IRF-3, and IRF-7 to induce expression
of proinflammatory cytokines [233, 234]. The only report
on IRF-5 in malaria infection revealed that it is dispensable
in the production of IFN-𝛽 by splenocytes in response to
stimulation by AT-rich oligonucleotides that resemble those
in the malarial genome [61]. Another member, IRF-9, is
expressed constitutively in many cell types and unlike the
rest of the IRFs, it functions only when it dimerizes with
STAT1 and STAT2 to form an active trimeric complex,
known as ISGF3. This complex binds to ISRE and activates
ISGs [235, 236]. During nonlethal PyNN67 infection, IRF-
9 participates in the production of IFN-I to control parasite
growth [85]. A robust IRF-8-dependent amplification of IRF-
9 was detected in brain of mice infected with PbA [72].
These separate studies seem to hint on the possibility of more
IRFs involvement in the immune response during malaria
infection.
6. Future Perspectives
In Figure 1, we illustrate the different malarial ligands and
the various signaling pathways triggered to produce IFN-I
and proinflammatory cytokines in the liver and erythrocytic
stages.Though controversial, these studies demonstrated that
IFN-I [77] and IFN-𝛾 [94] produced during infection may
modulate the course of disease progression. However, the
same immune response that initially protects the host could
inevitably contribute to the pathogenesis of severe malaria
[66, 82, 94].
Thus far, the most effective malaria treatment is
administration of antimalarial drugs, Chloroquine (CQ) or
Artemisinin (ART) and its derivatives, which solely targets
the parasite. But the emergence of CQ/ART-resistance
parasite species rendered these treatments increasingly
ineffective [237, 238]. In the recent years, increased
knowledge of the host immune response uncovers a potential
to employ host-directed therapy in malaria infection. In
fact, immunotherapy has emerged as a hot topic for both
research and treatment against a diverse array of disease
over the last few centuries [239–241]. Specifically, interferon
therapy has been widely reported to treat cancer [242–246]
and viral infections [247–249]. Recently, a synthetic innate
defense regulator-1018 (IDR-1018) adjunctive treatment, in
combination with antimalarial drug, demonstrated efficacy
against ECM [250]. Taken together, these data offer the
possibility of interferon treatment as an immunotherapy
for malaria infection. Thus, dissecting the innate signaling
pathways and their corresponding cytokine responses would
provide further insights into the induction of adaptive
immune response and offer some directions on vaccine or
drug developments.
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